Amyloid-beta and depression in healthy older adults: A systematic review

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 1, 2015, Pages 36-46

  Harrington, Karra D ^a,b   Lim, Yen Ying ^b,c   Gould, Emma ^a   Maruff, Paul ^b,d  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BROWN UNIVERSITY   (United States)

^d CogState Ltd ^*  (Australia)

Author keywords

Alzheimer's disease; Amyloid ; Depression

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; COGNITION; DSM-III; DSM-IV; DYSTHYMIA; EXECUTIVE FUNCTION; GERIATRIC DEPRESSION SCALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; ICD-10; LANGUAGE; MAJOR DEPRESSION; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; ONSET AGE; OUTCOME VARIABLE; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SYSTEMATIC REVIEW; TEMPORAL LOBE; VERBAL MEMORY; VISUAL MEMORY; AGING; BLOOD; BRAIN; COMPLICATION; CROSS-SECTIONAL STUDY; GERIATRIC ASSESSMENT; METABOLISM; STATISTICS AND NUMERICAL DATA; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; GERIATRIC ASSESSMENT; HUMANS; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84919432546     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414557161     Document Type: Review

References (62)

1. Albert MS. Changes in cognition. Neurobiology of Aging. 2011 ; 32: S58 - S63
2. Albert MS, Blacker D, Moss MB, et al. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology. 2007 ; 21: 158-169
3. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers and Dementia. 2011 ; 7: 270-279
4. Alves L, Correia ASA, Miguel R, et al. Alzheimer's disease: A clinical-practice-oriented review. Frontiers in Neurology. 2012 ; 3: 63
5. Baba HY, Nakano H, Maeshima E, et al. Metabolism of amyloid-β protein may be affected in depression. Journal of Clinical Psychiatry. 2012 ; 73: 115-120
6. Blasko I, Kemmler G, Jungwirth S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. American Journal of Geriatric Psychiatry. 2010 ; 18: 973-982
7. Butters MA, Klunk WE, Mathis CA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Disease and Associated Disorders. 2008 ; 22: 261-268
8. Byers AL, Yaffe K. Depression and risk of developing dementia. Nature Reviews Neurology. 2011 ; 7: 323-331
9. Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proceedings of National Academy of Sciences U S A. 2011 ; 108: 14968-14973
10. Cohen J Statistical power analysis for the behavioural sciences. New York: Academic Press ; 1988 :
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 ; 261: 921-923
12. Da Silva J, Gonçalves-Pereira M, Xavier M, et al. Affective disorders and risk of developing dementia: Systematic review. British Journal of Psychiatry. 2013 ; 202: 177-186
13. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology. 2012 ; 79: 1636-1644
14. Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurology. 2004 ; 3: 246-248
15. Ellis KA, Bush AI, Darby D, et al. The Australian imaging, biomarkers and lifestyle study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics. 2009 ; 21: 672-687
16. Gudmundsson PI, Skoog M, Waern K, et al. The relationship betwen cerebrospinal fluid biomarkers and depression in elderly women. The American Journal of Geriatric Psychiatry. 2007 ; 15 ( 10 ):
17. Harrington KD, Lim YY, Ellis KA, et al. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. International Psychogeriatrics. 2013 ; 25: 1667-1677
18. Hedden T, Oh H, Younger AP, et al. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013 ; 80: 1341-1348
19. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends in Biotechnology. 2011 ; 29: 26-32
20. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology. 2010 ; 9: 119-128
21. Kita Y, Baba H, Maeshima H, et al. Serum amyloid protein in young and elderly depression: A pilot study. Psychogeriatrics. 2009 ; 9: 180-185
22. Kramberger MGV, Jelic I, Kåreholt D, et al. Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra. 2012 ; 2: 48-56
23. Kumar A, Kepe V, Barrio JR, et al. Protein binding in patients with late-life depression. Archives of General Psychiatry. 2011 ; 68: 1143-1150
24. Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. American Journal of Geriatric Psychiatry. 2009 ; 17: 493-502
25. Lim YY, Ellis KA, Harrington K, et al. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease. Neuropsychology. 2013a ; 27: 322-332
26. Lim YY, Ellis KA, Harrington K, et al. Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β : Prodromal Alzheimer's disease?. Journal of Alzheimers Disease. 2013b ; 33: 1167-1176
27. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain. 2014a ; 137: 221-231
28. Lim YY, Pietrzak R, Ellis K, et al. Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers and Dementia.. 2014b ;:
29. Lim YY, Pietrzak RH, Ellis KA, et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β . Journal of Alzheimers Disease. 2013c ; 33: 675-679
30. Luppa M, Luck T, Ritschel F, et al. Depression and incident dementia. An 8-year population-based prospective study. PLoS ONE. 2013 ; 8: e59246
31. Madsen K, Hasselbalch BJ, Frederiksen KS, et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiology of Aging. 2012 ; 33: 2334-2342
32. Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Annals of Neurology. 2013 ; 73: 751-761
33. Moon YS, Kang SH, No HJ, et al. The correlation of plasma Aβ 42 levels, depressive symptoms, and cognitive function in the Korean elderly. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 ; 35: 1603-1606
34. Namekawa Y, Baba H, Maeshima H, et al. Heterogeneity of elderly depression: Increased risk of Alzheimer's disease and Aβ protein metabolism. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013 ; 43: 203-208
35. Neubauer A, Wahl H-W, Bickel H. Depressive symptoms as predictor of dementia versus continuous cognitive decline: A 3-year prospective study. European Journal of Ageing. 2013 ; 10: 37-48
36. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Archives of Neurology. 2001 ; 58: 1985-1992
37. Piccinni A, Origlia N, Veltri A, et al. Neurodegeneration, β -amyloid and mood disorders: State of the art and future perspectives. International Journal of Geriatric Psychiatry. 2013 ; 28: 661-671
38. Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. American Journal of Psychiatry. 2012 ; 169: 523-530
39. Pomara NPM, Doraiswamy LM, Willoughby AE, et al. Elevation in plasma Abeta42 in geriatric depression: A pilot study. Neurochemical Research. 2006 ; 31: 341-349
40. Prvulovic D, Hampel H. Amyloid β (Aβ ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clinical Chemistry and Laboratory Medicine. 2011 ; 49: 367-374
41. Qiu WQX, Sun DJ, Selkoe DM, et al. Depression is associated with low plasma Aβ 42 independently of cardiovascular disease in the homebound elderly. International Journal of Geriatric Psychiatry. 2007 ; 22: 536-542
42. Rapp MA, Hellweg R, Heinz A. [The importance of depressive syndromes for incipient Alzheimer-type dementia in advanced age]. Der Nervenarzt. 2011 ; 82: 1140-1144
43. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Archives of General Psychiatry. 2006 ; 63: 161-167
44. Reis T, Brandão CO, Freire Coutinho ES, et al. Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: Preliminary findings from Brazil. CNS Neuroscience and Therapeutics. 2012 ; 18: 524-529
45. Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurology. 2013 ; 70: 383-389
46. Small GW, Siddarth P, Kepe V, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Archives of Neurology. 2012 ; 69: 215-222
47. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers and Dementia. 2011 ; 7: 280-292
48. Sperling RA, Johnson KA, Doraiswamy PM, et al. Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging. 2013 ; 34: 822-831
49. Stomrud E, Hansson O, Zettrberg H, et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Archives of Neurology. 2010 ; 67: 217-223
50. Sun X, Bhadelia R, Liebson E, et al. The relationship between plasma amyloid-β peptides and the medial temporal lobe in the homebound elderly. International Journal of Geriatric Psychiatry. 2011 ; 26: 593-601
51. Sun X, Chiu CC, Liebson E, et al. Depression and plasma amyloid β peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Disease and Associated Disorders. 2009 ; 23: 238-244
52. Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: A prodromal depression of Alzheimer disease?. Archives of General Psychiatry. 2008 ; 65: 542-550
53. Sun XDM, Mwamburi K, Bungay J, et al. Depression, Antidepressants, and Plasma Amyloid β (Beta) Peptides in Those Elderly Who Do Not Have Cardiovascular Disease. Biological Psychiatry. 2010 ; 62: 1413-1417
54. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomarkers in Medicine. 2010 ; 4: 65-79
55. Tsuno N, Homma A. What is the association between depression and Alzheimer's disease?. Expert Review of Neurotherapeutics. 2009 ; 9: 1667-1676
56. Vilalta-Franch J, López-Pousa S, Llinàs-Reglà J, et al. Depression subtypes and 5-year risk of dementia and Alzheimer disease in patients aged 70 years. International Journal of Geriatric Psychiatry. 2013 ; 28: 341-350
57. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology. 2011 ; 69: 181-192
58. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurology. 2009 ; 8: 619-627
59. Wells CE. Pseudodementia. American Journal of Psychiatry. 1979 ; 136: 895-900
60. Wilson RS, Leurgans SE, Boyle PA. Neurodegenerative basis of age-related cognitive decline. Neurology. 2010 ; 75: 1070-1078
61. World Health Organisation. (2012) Dementia. Available at: www.who.int/mediacentre/factsheets/fs362/en/.
62. Wu KY, Hsiao IT, Chen CS, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: Evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. European Journal of Nuclear and Molecular Imagingg. 2014 ; 41: 714-722